Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Newsome JR, Venkatramani R, Heczey A, Danysh HE, Fishman DS, Miloh T. Cholangiocarcinoma among children and adolescents: a review of the literature and SEER-Database analysis. J Pediatr Gastroenterol Nutr. 2018 Jan 1;66(1):e12-8. doi: 10.1097/MPG.0000000000001749
Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegard A, Torp-Pedersen T, Perez-Gutthann S, Arana A. Ophthalmic nepafenac use in the Netherlands and Denmark. Acta Ophthalmol. 2017 Aug;95(5):509-17. doi: 10.1111/aos.13468
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Hartman EE, Pawaskar M, Williams V, McLeod L, Dubois D, Benninga MA, Joseph A. Psychometric properties of PedsQL generic core scales for children with functional constipation in the Netherlands. J Pediatr Gastroenterol Nutr. 2014 Dec;59(6):739-47. doi: 10.1097/MPG.0000000000000527
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.